SRPKIN-1|cas:2089226-94-6|西域试剂

SRPKIN-1,98.56%

产品编号：Bellancom-116856| CAS NO：2089226-94-6| 分子式：C₂₇H₂₁FN₂O₃S| 分子量：472.53

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-116856	￥3500.00	杭州北京（现货）
Bellancom-116856	￥5500.00	杭州北京（现货）
Bellancom-116856	￥16500.00	杭州北京（现货）
Bellancom-116856	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SRPKIN-1

产品介绍

SRPKIN-1是共价，不可逆的 SRPK1/2 抑制剂，IC₅₀ 分别为35.6 和 98 nM。有抗血管生成作用。

生物活性

SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC₅₀s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.

体外研究

SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout.

SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Ba/F3 cells
Concentration:	0-10000 nM
Incubation Time:	72 h
Result:	Potently decreased the level of SR phosphorylation in a dose-dependent manner, leading to increased VEGF-A165b RNA as well as protein even at a dose of 200 nM.

体内研究
(In Vivo)

SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	50 nM, 300 nM, 1 μL
Administration:	Intravitreal injection, 5 times
Result:	SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area.

体内研究

SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	50 nM, 300 nM, 1 μL
Administration:	Intravitreal injection, 5 times
Result:	SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area.

体内研究

SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	50 nM, 300 nM, 1 μL
Administration:	Intravitreal injection, 5 times
Result:	SRPKIN-1-treated mice is significantly suppressed in a dose-dependent manner based upon measurement of the CNV area.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 110 mg/mL (232.79 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1163 mL	10.5813 mL	21.1627 mL
5 mM	0.4233 mL	2.1163 mL	4.2325 mL
10 mM	0.2116 mL	1.0581 mL	2.1163 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.75 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (5.82 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.75 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (5.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。